Nefropatía diabética
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
La Nefropatía diabética es una de las más graves complicaciones crónicas de la diabetes mellitus, se presenta cinco a diez años después del inicio de la enfermedad y es consecuencia de la asociación de factores tales como mal control glicémico, dislipidemia, consumo de cigarrillo, hipertensión arterial, etc; sin embargo, algunos pacientes, independientemente de presentar estos factores o no, sufrirán esta complicación. Existe evidencia en la literatura de que varios mecanismos hereditarios pueden estar implicados y numerosos genes han sido propuestos como candidatos a ser generadores de mayor susceptibilidad a Nefropatía diabética; lo que abre puertas para varias opciones de tratamiento como terapia génica. Este documento tiene como propósito hacer una revisión sobre esta patología, dada su importancia por la alta morbilidad y mortalidad en la población diabética. Hablaremos sobre su epidemiología, clínica, fisiopatología, diagnóstico y tratamiento, con un mayor énfasis en los aspectos genéticos, área en la que se han abierto puertas para el desarrollo de nuevas opciones de tratamiento.
Citas
Cordovado SK, Zhao Y, et al. Nephropathy in type 1 diabetes is diminished in carriers of HLA-DRB1*04: the genetics of kidneys in diabetes (GoKinD) study. Diabetes.2008;57(2): 518-22.
Majaliwa ES, Munubhi E, et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care.2007;30(9):2187- 92.
Monti MC, Lonsdale JT, et al. Familial risk factors for microvascular complications and differential malefemale risk in a large cohort of American families with type 1 diabe
Soltesz G, Patterson CC, et al. Worldwide childhood type 1 diabetes incidence--what can we learn from epidemiology?. Pediatr Diabetes.2007;8 Suppl 6:6- 14.
Girach A, Manner D, et al. Diabetic microvascular complications: can patients t risk be identified? A review. Int J Clin Pract.2006 ;60(11):1471-83.
Villar E, Chang SH, et al. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991 2005). Diabetes Care.2007;30(12):3070-6.
Ewens KG, George RA, et al. Assessment of 115 candidate genes for diabetic nephropathy by transmission/ disequilibrium test. Diabetes.2005;54(11):3305-18.
Yishak AA, Costacou T, et al. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant.2006; 21(1):93-100.
Niehof M, Borlak J. HNF4 alpha and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy. Diabetes.2008;57(4):1069-77.
Sochett EB, Cherney DZ, et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol .2006;17(6):1703-9.
Donaghue KC, Chiarelli F, et al. ISPAD clinical practice consensus guidelines 2006-2007. Microvascular and macrovascular complications. Pediatr Diabetes; 2007;8(3):163-70.
Ladeia AM, Ladeia-Frota C, et al. Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care.2005; 28(8):2048-50.
Zerbini G, Bonfanti R, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2006 55(9):2620-5.
Vélez H, Rojas W. Endocrinología. 6. ed. Medellín: CIB; 2006
Gerth J, Cohen CD, et al. Collagen type VIII expression in human diabetic nephropathy. Eur J Clin Invest.2007;37(10):767-73.
Ichinose K, Kawasaki E, et al. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol.2007;27(6): 554-64.
Glastras SJ, Mohsin F, et al. Complications of diabetes mellitus in childhood. Pediatr Clin North Am.2005;52(6):1735-53.
Raes A, Donckerwolcke R, et al. Renal hemodynamic changes and renal functional reserve in children with type I diabetes mellitus. Pediatr Nephrol.2007;22(11):1903- 9.
Beisswenger PJ, Drummond KS, et al. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes.2005;54(11):3274-81.
Avner ED, Harman WE, Niaudet P, editors. Pediatric Nephrology. 5. ed. Philadelphia: Lippincott Williams & Wilkins; 2004
Mostafa AA, Randell EW, et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem.2007;302(1-2):35-42.
Lane PH. Diabetic kidney disease: impact of puberty. Am J Physiol Renal Physiol.2002; 283(4):F589-600.
Cherney DZ, Miller JA, et al. The effect of cyclooxygenase2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes.2008;57(3):688-95.
Skrivarhaug T, Bangstad HJ, et al. (2006). Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatr Diabetes.2006;7(5): 239-46.
Perrin NE, Torbjornsdotter TB, et al.The course of diabetic glomerulopathy in patients with type I diabetes: a 6-year follow-up with serial biopsies. Kidney Int 2006; 69(4): 699-705.
Hasslacher C. (10). Hypertension in Diabetic Nephropaty. Diabetic Nephropaty. Hasslacher.
Chiarelli F, Trotta D, et al. Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus.Pediatr Diabetes.2002;3(2):113- 24.
Bogdanovic R. Diabetic nephropathy in children. Nephrol Dial Transplant.2001;16 Suppl 6: 120-2.
Perkins BA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes.N Engl J Med.2003;348(23):2285-93.
Nitsch D, Burden R, et al. Patients with diabetic nephropathy on renal replacement therapy in England and Wales. QJM.2007;100(9):551-60.
McKnight AJ, Maxwell AP, et al. A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy.J Am Soc Nephrol.2006;17(3):831- 6.
Cao C, Hellermann JP, et al. Time trends in the epidemiology of renal transplant patients with type 1 diabetes mellitus over the last four decades.Nephrol Dial Transplant.2006; 21(3):770-5.
Carel JC, Levy-Marchal C.Renal complications of childhood type 1 diabetes. BMJ. 2008;336(7646):677- 8.
Raile K, Galler A, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care.2007;30(10):2523-8.
Osterholm AM, He B, et al. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int. 2007; 71(2):140-5.
McKnight AJ, Savage DA, et al. Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy. J Hum Genet.2006;51(4):383-6.
Vardarli I, Baier LJ, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int.2002;62(6):2176-83.
McKnight AJ, Maxwell AP, et al. Association of VEGF-1499C-->T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. J Diabetes Complications.2007;21(4): 242-5.
McKnight AJ, Savage DA, et al. Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med Genet.2007;8:5.
Steinke JM, Sinaiko AR, et al. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5- year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes.2005;54(7):2164- 71.
American Diabetes Association. Standards of medical care in diabetes--2006.Diabetes Care.2006;29 Suppl1: S4-42.
American Diabetes Association. Standards of medical care in diabetes--2008.Diabetes Care.2008;31 Suppl1: S12-54
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.-Diabetes. 2005;54(6):1615- 1625.
Dunger DB, Schwarze CP, et al. Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria?. Diabet Med. 2007;24(2):131-6.
Ficociello LH, Perkins BA, et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol.2007;2(3):461-9.
Amin R. Is glomerular filtration rate in children after 5 years of type 1 diabetes associated with development of albuminuria?. Nature. 2006;2 (5):242-243.
Perkins BA, Ficociello LH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol.2007;18(4):1353- 61.
Chiarelli F, Trotta D, et al. Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes.2002;3(2):113- 24.
Brenner BM, Cooper ME, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med.2001;345(12):861-9.
Perrin NE, Jaremko GA, et al. The effects of candesartan on diabetes glomerulopathy: a double-blind, placebocontrolled trial. Pediatr Nephrol.2008;23(6):947-54.
Goodfriend TL, Elliott ME, et al. Angiotensin receptors and their antagonists.N Engl J Med.1996;334(25):1649- 54.
Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a metaanalysis. Diabet Med. 2007;24(5):486-493.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med.2008;358:1547-1559.
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet.2007;370:221–29
Gradman AH, Pinto R, Kad R. Current concepts: renin inhibition in the treatment of hypertension. Curr Opin Pharmacol.2008;8:120–126.
Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs.2006;66(18):2287- 98.